| The endless quarantine: the impact of the COVID-19 outbreak on healthcare workers after three months of mandatory social isolation in Argentina DL Giardino, C Huck-Iriart, M Riddick, A Garay Sleep medicine 76, 16-25, 2020 | 86 | 2020 |
| PET‐adapted therapy after three cycles of ABVD for all stages of Hodgkin lymphoma: results of the GATLA LH‐05 trial A Pavlovsky, I Fernandez, N Kurgansky, V Prates, L Zoppegno, P Negri, ... British Journal of Haematology 185 (5), 865-873, 2019 | 13 | 2019 |
| PET-CT adapted therapy after 3 cycles of ABVD to all stages of Hodgkin lymphoma. GATLA trial HL-05 A Pavlovsky, I Fernandez, N Kurgansky, V Prates, L Zoppegno, P Negri, ... Haematologica 101, 5-5, 2016 | 5 | 2016 |
| Impact of Ibrutinib in quality of life (QoL) in patients with chronic lymphocytic leukemia (CLL): preliminary results of real-world experience MJ Mela Osorio, C Pavlovsky, A Pavlovsky, I Fernandez, FS Massa, ... Elsevier, 2018 | 3 | 2018 |
| P1081: PET-adapted therapy after three cycles of ABVD for all stages of Hodgkin lymphoma: long term follow up of the GATLA LH-05 trial A Pavlovsky, NL Fiad, MV Prates, I Fernandez, N Kurgansky, A Cerutti, ... HemaSphere 6, 971-972, 2022 | 2 | 2022 |
| High Level of Successful TKI Discontinuation in Chronic Myeloid Leukemia (CML) Patients: Preliminary Results of AST-Argentina Stop Trial C Pavlovsky, AI Varela, II Fernandez, MB Sanchez, MDR Custidiano, ... Blood 136, 3-5, 2020 | 2 | 2020 |
| Estimación Bayesiana en el modelo de riesgos aditivos ML Riddick Universidad Nacional de La Plata, 2020 | 2 | 2020 |
| P715: MULTICENTER OBSERVATIONAL STUDY OF PONATINIB IN CML PATIENTS IN ARGENTINA. REAL‐WORLD EXPERIENCE. MJ Mela Osorio, MV Osycka, B Moiraghi, MA Pavlovsky, AI Varela, ... HemaSphere 6, 610-611, 2022 | 1 | 2022 |
| P715: MULTICENTER OBSERVATIONAL STUDY OF PONATINIB IN CML PATIENTS IN ARGENTINA. REAL-WORLD EXPERIENCE. MJM Osorio, MV Osycka, B Moiraghi, MA Pavlovsky, AI Varela, ... HemaSphere 6, 610-611, 2022 | 1 | 2022 |
| MTV, TLG AND SUV MAX AS PROMISING PARAMETERS TO PREDICT EARLY RESPONSE IN PATIENTS WITH HL TREATED WITH ABVD. A RETROSPECTIVE SUB‐ANALYSIS OF THE GATLA‐LH‐05 TRIAL J Iorio, M Eleta, V Plates, L Fiad, M Riddick, A Pavlovsky Hematological Oncology 39, 2021 | 1 | 2021 |
| Local structural investigation across the magnetic transition in the type-II multiferroic material G Bera, A Surampalli, ML Riddick, VR Reddy, VG Sathe, GR Turpu, ... Physical Review B 109 (7), 075138, 2024 | | 2024 |
| Stochastic approaches: modeling the probability of encounters between H-molecules and metallic atomic clusters in a cubic box ML Riddick, EE Álvarez, FG Requejo, L Andrini arXiv preprint arXiv:2301.13797, 2023 | | 2023 |
| Impact of Ibrutinib in Quality of Life (QoL) in Patients with Chronic Lymphocytic Leukemia (CLL): Real World Experience in Argentina MJ Mela Osorio, A Pavlovsky, C Pavlovsky, II Fernandez, M Clavijo, ... Blood 140 (Supplement 1), 12403-12404, 2022 | | 2022 |
| PET‐ADAPTED THERAPY AFTER THREE CYCLES OF ABVD FOR ALL STAGES OF HODGKIN LYMPHOMA: LONG TERM FOLLOW UP OF THE GATLA LH‐05 TRIAL A Pavlovsky, L Fiad, I Fernandez, V Prates, N Kurgansky, A Cerutti, ... Hematological Oncology 39, 2021 | | 2021 |
| In Pursuit of Surrogate Markers for Treatment-Free Remission in Patients with Chronic Myeloid Leukemia from Argentina Stop Trial MB Sanchez, B Moiraghi, AI Varela, E Levy, M Vera, BV Cordoba, I Giere, ... Blood 136, 24, 2020 | | 2020 |
| A machine learning approach applied to determine formal oxidation state of 3D compounds CH Iriart, SJA Figueroa, LR Andrini, ML Riddick Brazilian Synchrotron Light Laboratory, 2020 | | 2020 |
| PB1903 IMPROVEMENT IN PATIENT-REPORTED OUTCOMES (PROS) AND FATIGUE IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA TREATED WITH IBRUTINIB (IBR) MONOTHERAPY: REPORT OF REAL WORLD … MJM Osorio, A Pavlovsky, I Fernández, C Pavlovsky, FS Massa, L Ferrari, ... HemaSphere 3 (S1), 867-868, 2019 | | 2019 |
| Review of bayesian analysis in additive hazards model EE Alvarez, ML Riddick Asian Journal of Probability and Statistics 4, 2019 | | 2019 |
| A Retrospective Multicenter Analysis of the Safety and Efficacy of Brentuximab Vedotin (BV) As Monotherapy or in Combination with Bendamustine (BV-B) in Relapsed Refractory … F Negri Aranguren, S Cranco, C Shanley, II Fernandez, MV Prates, ... Blood, The Journal of the American Society of Hematology 130 (Suppl_1), 4089 …, 2017 | | 2017 |
| Brentuximab vedotin: A retrospective multicenter analysis of its indication, safety and efficacy in Argentina MF Negri Aranguren, C Shanley, S Cranco, V Otero, L Fiad, I Fernandez, ... Hematological Oncology 35, 320-321, 2017 | | 2017 |
